Axel Grothey, MD - Taking Aim at GI Cancers: New Opportunities to Deliver Personalized Treatment With HER2 and Other Molecularly Targeted Therapies


Manage episode 286268455 series 103583
著作 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education の情報はPlayer FM及びコミュニティによって発見されました。著作権は出版社によって所持されます。そして、番組のオーディオは、その出版社のサーバから直接にストリーミングされます。Player FMで購読ボタンをタップし、更新できて、または他のポッドキャストアプリにフィードのURLを貼り付けます。
Go online to to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers. Upon completion of this activity, participants should be better able to: Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status, Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection, Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others, Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences.

84 つのエピソード